OPKO Health Inc banner

OPKO Health Inc
NASDAQ:OPK

Watchlist Manager
OPKO Health Inc Logo
OPKO Health Inc
NASDAQ:OPK
Watchlist
Price: 1.235 USD 0.41%
Market Cap: $937.5m

EV/EBIT

-4.1
Current
16%
Cheaper
vs 3-y average of -4.9

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
-4.1
=
Enterprise Value
$863.7m
/
EBIT
$-219m

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
-4.1
=
Enterprise Value
$863.7m
/
EBIT
$-219m

Valuation Scenarios

OPKO Health Inc is trading above its industry average

If EV/EBIT returns to its Industry Average (14.3), the stock would be worth $-4.26 (445% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-575%
Maximum Upside
No Upside Scenarios
Average Downside
510%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple -4.1 $1.24
0%
Industry Average 14.3 $-4.26
-445%
Country Average 19.6 $-5.86
-575%

Forward EV/EBIT
Today’s price vs future ebit

Not enough data available to calculate forward EV/EBIT

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
US
OPKO Health Inc
NASDAQ:OPK
933.7m USD -4.1 -4.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -192 227.3 -160 127.7
US
Abbvie Inc
NYSE:ABBV
354.5B USD 19.6 84.7
US
Amgen Inc
NASDAQ:AMGN
186.5B USD 14.1 24.3
US
Gilead Sciences Inc
NASDAQ:GILD
164.9B USD 15.1 19.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.2B USD 22 28.1
US
Epizyme Inc
F:EPE
94.1B EUR -565.5 -533.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.9B USD 15.2 17.8
NL
argenx SE
XBRU:ARGX
42B EUR 42.4 38.4
US
Seagen Inc
F:SGT
39.3B EUR -60.1 -61.8
AU
CSL Ltd
ASX:CSL
62.3B AUD 13 30.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
OPKO Health Inc
NASDAQ:OPK
Average EV/EBIT: 20.2
Negative Multiple: -4.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
19.6
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.1
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.1
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.2
23%
0.7
NL
argenx SE
XBRU:ARGX
42.4
51%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
AU
CSL Ltd
ASX:CSL
13
10%
1.3
P/E Multiple
Earnings Growth PEG
US
OPKO Health Inc
NASDAQ:OPK
Average P/E: 34.7
Negative Multiple: -4.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
84.7
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.3
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
19.5
16%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
19%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
14%
1.3
NL
argenx SE
XBRU:ARGX
38.4
30%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
AU
CSL Ltd
ASX:CSL
30.4
9%
3.4

Market Distribution

Lower than 100% of companies in the United States of America
Percentile
0th
Based on 8 638 companies
0th percentile
-4.1
Low
0 — 13.6
Typical Range
13.6 — 27.8
High
27.8 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 13.6
Median 19.6
70th Percentile 27.8
Max 1 826 183.2

OPKO Health Inc
Glance View

In the bustling world of healthcare and biotechnology, OPKO Health Inc. stands as a unique and dynamic player. Founded by the ambitious mind of Dr. Phillip Frost, the company has woven itself into the fabric of diverse biomedical sectors. OPKO predicates its enterprise on the integration of complementary businesses ranging from diagnostics to pharmaceuticals, creating synergies that are not just theoretical, but markedly operational. At the heart of its operations lies the interplay between new drug discovery and diagnostics development, allowing OPKO to leverage cutting-edge technologies in crafting novel health solutions. By honing in on significant medical unmet needs, they aspire to deliver innovations that address chronic diseases such as diabetes, oncology, and neurological disorders. This strategic weaving together of distinct healthcare sectors manifests in OPKO's sprawling portfolio—from the renowned Rayaldee, which targets secondary hyperparathyroidism, to its advanced diagnostics segments, which include proprietary tests for specific cancers and other conditions. The company's revenue streams can be best visualized as an interlocking lattice of healthcare services and products. It earns through a blend of product sales, licensing, and collaborative agreements with other biotech and pharmaceutical giants. Rayaldee, as a potent testament to their R&D prowess, contributes robustly to their revenue, while the diagnostics division, powered by their substantial investment in technology and infrastructure, brings in consistent sales from various testing services. The company’s BioReference Laboratories, one of the largest full-service diagnostic laboratories in the U.S., also plays a critical role in their financial architecture, offering both routine and esoteric tests. Additionally, OPKO is involved in strategic collaborations and licensing arrangements, enhancing its market footprint and creating channels for revenue infusion through partnerships with industry leaders. Ultimately, OPKO Health Inc.'s narrative is one of leveraging diversified capabilities and strategic partnerships to carve out a formidable presence in the complex landscape of global healthcare.

OPK Intrinsic Value
1.182 USD
Overvaluation 4%
Intrinsic Value
Price $1.235
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett